ESMO 2021 Roundup

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

OncoAlert and ecancer - ESMO 2021 Day 3

MRD-guided therapy debate

OncoAlert and ecancer - ESMO 2021 Day 2

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

OncoAlert and ecancer - ESMO 2021 preview

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Should every transplant eligible NDMM patient receive a transplant?